IgA-nefropátia: vizsgálatok itt: Kína
53 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
- Where
- Beijing, Xi’an
- Életkor
- 2 év to 18 év
- People
- 28 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07498335 - 3. fázisTaking peopleA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Where
- Baotou, Beijing, Changping, Changsha, Chengdu, Guangdong, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Yibin, Zhuhai
- Életkor
- 18 év and over
- People
- 347 worldwide
- Run by
- Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00 - No phaseNot yet taking people in KínaMYTP01 for Immune-Mediated Diseases
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 160
- Run by
- Zhejiang Provincial People's Hospital
See details and how to joinNCT07901764 - 2. fázisTaking peopleEfficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 52
- Run by
- Kira Pharmacenticals (US), LLC.
See details and how to joinNCT05517980 - 4. fázisNot yet taking people in KínaEfficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Ruijin Hospital
See details and how to joinNCT07888335 - 2. fázisTaking peopleA Study to Assess the Effects of Zigakibart on IgA Nephropathy.
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 32 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00 - 1. fázisNot yet taking people in KínaIBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 100
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07886476 - 3. fázisTaking peopleA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Where
- Beijing, Cangzhou, Chengdu, Daqing, Fuyang, Fuzhou, Guangzhou, Guiyang, Hefei, Hong Kong, Jinan, Jinhua, Lanzhou, Luoyang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Yantai, Yichang, Zhongshan
- Életkor
- 18 év and over
- People
- 454 worldwide
- Run by
- Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00 - 3. fázisTaking peopleA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Beijing, Changchun, Changsha, Guangzhou, Luoyang, Ningbo, Qingdao, Shanghai, Shenzhen, Taiyuan, Ürümqi, Wenzhou, Xian, Yinchuan, Zhengzhou
- Életkor
- 18 év to 100 év
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - No phaseTaking peopleTo Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 374
- Run by
- Hong Zhang
See details and how to joinNCT07822100 - No phaseTaking peopleIgA Nephropathy Registration Initiative of High Quality (INSIGHT)
- Where
- Guangzhou
- Életkor
- 14 év and over
- People
- 10 000
- Run by
- Sun Yat-sen University
See details and how to joinNCT03001947 - No phaseTaking peopleCorrelation of Microbiome and Metabonomics With IgA Nephropathy
- Where
- Guangzhou, Guanzhou
- Életkor
- 16 év to 65 év
- People
- 600
- Run by
- Guangdong Provincial People's Hospital
See details and how to joinNCT05190848 - Korai 1. fázisNot yet taking people in KínaA Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Grit Biotechnology
See details and how to joinNCT07389499 - 3. fázisTaking peopleStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
- Where
- Beijing, Hangzhou
- Életkor
- 2 év to 18 év
- People
- 31 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06994845 - 2. fázisTaking peopleChinese Adults With Kidney Disease
- Where
- Baotou, Beijing, Guiyang, Shandong, Shanghai, Shenzhen, Wuxi, Yantai, Zhengzhou
- Életkor
- 18 év and over
- People
- 30
- Run by
- ADARx Pharmaceuticals, Inc.
See details and how to joinNCT07522099 - 4. fázisTaking peopleEfficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 288
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07604311 - No phaseTaking peopleThe Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- Where
- Shanghai
- People
- 2000
- Run by
- Ruijin Hospital
See details and how to joinNCT04858724 - No phaseNot yet taking people in KínaUniversal STAR-T Cell Injection in Autoimmune Kidney Diseases
- Where
- Guangdong
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Guangdong Provincial People's Hospital
See details and how to joinNCT07746453 - 2. fázisTaking peopleEvaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
- Where
- Beijing, Tianjin
- Életkor
- 18 év to 75 év
- People
- 45
- Run by
- Everest Medicines (China) Co.,Ltd.
See details and how to joinNCT07614477 - Korai 1. fázisTaking peopleA Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 96
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07203404 - 3. fázisTaking peopleStudy of Ravulizumab in Pediatric Participants With Primary IgAN
- Where
- Beijing, Shanghai
- Életkor
- 2 év to 18 év
- People
- 36 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07024563 · EU 2024-520167-13-00 - 2. fázisNot yet taking people in KínaPhase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 60
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07730632 - 2. fázisTaking peopleA Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 380
- Run by
- Chengdu Suncadia Medicine Co., Ltd.
See details and how to joinNCT07582133 - Korai 1. fázisNot yet taking people in KínaRD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
- Where
- Hangzhou, Nanjing
- Életkor
- 5 év to 20 év
- People
- 30
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07674147 - 2. fázisTaking peopleA Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
- Where
- Beijing
- People
- 73
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07616700